NanoRepro AG (FRA:NN6) ROC (Joel Greenblatt) %: -42.69% (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NN6 NanoRepro AG FRA:NN6
53 GF Score
Price €1.97
GF Value €0.99
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is NanoRepro AG ROC (Joel Greenblatt) %?

NanoRepro AG FRA:NN6 -5.74% 53 ROC (Joel Greenblatt) % is -42.69% as of Jun. 2025. GuruFocus rates FRA:NN6 with a GF Score™ of 53/100 and a GF Value™ of €0.99 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, NanoRepro AG ranks worse than 63.51% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. NanoRepro AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was -42.69%.

The historical rank and industry rank for NanoRepro AG's ROC (Joel Greenblatt) % or its related term are showing as below:

FRA:NN6' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -220.45   Med: -33.69   Max: 158.28
Current: -47.16

During the past 13 years, NanoRepro AG's highest ROC (Joel Greenblatt) % was 158.28%. The lowest was -220.45%. And the median was -33.69%.

FRA:NN6's ROC (Joel Greenblatt) % is ranked worse than
63.51% of 211 companies
in the Medical Diagnostics & Research industry
Industry Median: -3.02 vs FRA:NN6: -47.16

NanoRepro AG's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


NanoRepro AG  (FRA:NN6) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


NanoRepro AG ROC (Joel Greenblatt) % Related Terms


NanoRepro AG ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for NanoRepro AG's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NanoRepro AG ROC (Joel Greenblatt) % Chart

NanoRepro AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 53.62 158.28 -16.22 -32.15 -35.23

NanoRepro AG Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -37.04 -36.77 -47.66 -45.44 -42.69

FRA:NN6 vs TMO, DHR, IDXX: ROC (Joel Greenblatt) % Comparison

For the Diagnostics & Research subindustry, NanoRepro AG's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NanoRepro AG ROC (Joel Greenblatt) % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NanoRepro AG's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where NanoRepro AG's ROC (Joel Greenblatt) % falls into.


FRA:NN6
53GF Score
NanoRepro AG FRA:NN6
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NanoRepro AG ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.265 + 0.901 + 4.411) - (0.293 + 0 + 0.006)
=5.278

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.428 + 0.466 + 1.842) - (0.217 + 0 + 0.097)
=2.422

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of NanoRepro AG for the quarter that ended in Jun. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Jun. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2024  Q: Jun. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.792/( ( (0.347 + max(5.278, 0)) + (0.349 + max(2.422, 0)) )/ 2 )
=-1.792/( ( 5.625 + 2.771 )/ 2 )
=-1.792/4.198
=-42.69 %

Note: The EBIT data used here is two times the semi-annual (Jun. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -42.69% mean?
NanoRepro AG (FRA:NN6) has a ROC (Joel Greenblatt) % of -42.69% as of Jun. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on NanoRepro AG and its competitors. According to the industry distribution chart, NanoRepro AG ranks #134 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 63.5%.
Is NanoRepro AG's ROC (Joel Greenblatt) % too high?
NanoRepro AG's current ROC (Joel Greenblatt) % is -42.69%. Based on the distribution chart, NanoRepro AG ranks #134 out of 211 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, NanoRepro AG has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NanoRepro AG's ROC (Joel Greenblatt) % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, NanoRepro AG ranks #134 out of 211 companies for ROC (Joel Greenblatt) %. This places NanoRepro AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Diagnostics & Research company?
A good ROC (Joel Greenblatt) % depends on the Medical Diagnostics & Research industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on NanoRepro AG and its competitors. NanoRepro AG's current ROC (Joel Greenblatt) % is -42.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NanoRepro AG stock overvalued right now?
Based on GuruFocus' analysis, NanoRepro AG (FRA:NN6) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.99, compared to a current price of €1.97 — trading 99% above its estimated fair value. The current ROC (Joel Greenblatt) % is -42.69%. NanoRepro AG's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For NanoRepro AG (FRA:NN6), the current ROC (Joel Greenblatt) % is -42.69% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NanoRepro AG (FRA:NN6) Overvalued in 2026?

Based on GuruFocus' analysis, NanoRepro AG stock appears to be overvalued. The current stock price of €1.97 is trading 99% above its estimated GF Value™ of €0.99. GuruFocus considers NanoRepro AG to be Significantly Overvalued.

Key valuation signals for FRA:NN6:

  • ROC (Joel Greenblatt) %: -42.69%
  • GF Value™: €0.99 vs. price of €1.97 (99% above fair value)
  • GF Score™: 53/100 with 6 warning signs

No single metric tells the full story. See the FRA:NN6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NanoRepro AG Business Description

Other Exchanges NN6:Germany
Address Untergasse 8, Marburg, DEU, 35037
NanoRepro AG is engaged in the development, manufacturing, and distribution of CE-certified rapid diagnostic tests (self-tests) and food supplements for both, home and professional use.
53GF Score

Get the complete analysis for FRA:NN6

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.97
Price
€0.99
GF Value